Sign up for the email list

I just wanted to say Thank You for taking the time to come to my school and present on seizure disorders. It was helpful and I really appreciated your... Harriett, School Nurse

UCB announces Positive Results in a Trial designed for the Goal of a Monotherapy Indication for VIMPAT (LACOSAMIDE)
This week UCB announced positive and exciting first results of a Phase III study designed to evaluate the efficacy and safety of conversion to Vimpat® (lacosamide) monotherapy in adult epilepsy patients with partial-onset seizures with or without secondary generalization.
These new data support our development of Vimpat as monotherapy for partial onset seizures and our goal to make it available to many more people living with epilepsy worldwide. UCB plans to submit these data to the U.S. Food & Drug Administration during the second half of 2013 as part of our supplemental New Drug Application for Vimpat.
Vimpat is currently approved as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy (ages ≥ 17 years). It is available in 36 countries worldwide and has been used by over 230,000 patients.

For more information, read the  full press release from UCB.

Back To All News
Home      About Us      Events      News      Programs and Services      Photos      Advocacy      Epilepsy Facts      Volunteers      Research      Contact Us

© 2015 Epilepsy Foundation Connecticut   |   (860) 346-1924 or (800) 899-3745   |   386 Main St Middletown, CT, 06457-3360   |  en español

Creative Sunrise Web Development